Welcome to our dedicated page for Minerva Neurosciences SEC filings (Ticker: NERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Minerva Neurosciences, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company focused on central nervous system disorders. Form 8-K reports cover results of operations and financial condition, Regulation FD materials, roluperidone clinical-development disclosures, annual meeting timing, and material corporate events involving officers, directors, compensation arrangements, and governance.
Definitive proxy statements describe stockholder meeting procedures, board elections, voting matters, executive compensation, and corporate-governance practices. The filings also identify Minerva’s common stock listed on The Nasdaq Capital Market and provide formal disclosure around financing arrangements, board composition, and the company’s roluperidone program for negative symptoms of schizophrenia.
Minerva Neurosciences director Inderjit Kaul received a stock option grant for 12,169 shares of Common Stock at an exercise price of $6.03 per share. The option expires on March 30, 2036 and is structured as performance- and time-based compensation, not an open-market share purchase or sale.
According to the vesting terms, 25% of the option vests on November 14, 2026. An additional 45% vests on the tenth day after Minerva publicly announces that its Phase 3 confirmatory trial of roluperidone in schizophrenia has achieved the primary endpoint at the 12-week timepoint on a statistically significant basis. The remaining 30% vests on the tenth day after Minerva publicly announces safety data from the 40-week relapse assessment phase, provided Kaul is providing services under a consulting agreement dated November 14, 2025 on each vesting date.
Federated Hermes Kaufmann Fund II reported a sale of 3,658 shares of Common Stock of NERV.
The filing shows the transaction date as 03/10/2026 and an aggregate amount of $29,331.18. The Form 144 notice lists prior "Securities To Be Sold" activity including a 17,225-share secondary/open-market entry dated 04/15/2015.
Federated Hermes Kaufmann Small Cap Fund reported a sale of 97,549 shares of Common Stock of NERV on 03/10/2026 for $743,274.98. The filing also lists a prior entry showing 534,050 shares of Common Stock described as "Secondary Offering/Open Market" dated 04/15/2015 with Cash as the consideration type.
NERV submitted a Form 144 reporting a proposed resale of 650,000 shares of Common Stock. The filing also records an actual sale of 156,410 shares on 03/10/2026 for $1,191,767.01. The excerpt lists 43,274,396 shares outstanding as of 03/31/2026.
Registration covers up to $200,000,000 of securities. Minerva Neurosciences is registering an at‑the‑market shelf to offer, from time to time, up to $200,000,000 of common stock, preferred stock, debt securities and warrants, alone or in combination. The prospectus is a shelf framework; specific terms and proceeds will be set in prospectus supplements.
The filing discloses clinical plans for the lead candidate, roluperidone: a Phase 3 C19 trial expected to start in Q2 2026 enrolling 380 patients with topline efficacy in 2H 2027 and relapse data in 2H 2028. As of February 28, 2026, 43,274,398 shares of common stock were outstanding.
Minerva Neurosciences reports 2025 results and details next steps for its lead drug, roluperidone, after receiving an FDA Complete Response Letter in February 2024. The company is a clinical‑stage CNS biopharmaceutical developer focused on negative symptoms of schizophrenia.
Minerva plans a new 380‑patient Phase 3 confirmatory trial (C19) of once‑daily 64 mg roluperidone versus placebo, with first patient screening expected in the second quarter of 2026, a 12‑week primary endpoint on the PANSS Marder negative symptoms factor score, and a 40‑week relapse‑assessment phase. Topline efficacy data are expected in the second half of 2027 and relapse data in the second half of 2028.
The company recorded a 2025 net loss of $293.4 million, compared with net income of $1.4 million in 2024, and had an accumulated deficit of $688.8 million as of December 31, 2025. Minerva highlights extensive business risks, including continued losses, reliance on additional capital, and dependence on roluperidone’s clinical and regulatory success.
Minerva Neurosciences reported a large GAAP net loss of $293.4 million for 2025, driven mainly by a $321.5 million non-cash loss on the issuance of Series A convertible preferred stock and warrants, partly offset by a $45.4 million gain from the change in warrant fair value.
On a non-GAAP basis, adjusted net loss for 2025 was $16.0 million, improving from $19.3 million in 2024 as operating expenses fell, especially research and development. Cash, cash equivalents and restricted cash rose to $82.4 million at December 31, 2025 from $21.5 million a year earlier, mainly from an October 2025 private placement.
That financing delivered $80.0 million in gross proceeds and included Tranche A and Tranche B warrants that could provide up to an additional $120.0 million if fully exercised. The company plans to initiate a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027.